Ascendis Pharma A/S (NASDAQ:ASND) Receives Average Rating of “Moderate Buy” from Analysts

Ascendis Pharma A/S (NASDAQ:ASND) has been given a consensus rating of “Moderate Buy” by the thirteen brokerages that are covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and twelve have issued a buy recommendation on the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $191.77.

A number of equities analysts have commented on the stock. StockNews.com raised shares of Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research note on Wednesday. Stifel Nicolaus raised their price target on shares of Ascendis Pharma A/S from $200.00 to $207.00 and gave the stock a “buy” rating in a report on Friday, November 15th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $170.00 price objective on shares of Ascendis Pharma A/S in a report on Friday, November 15th. Oppenheimer cut their target price on Ascendis Pharma A/S from $190.00 to $180.00 and set an “outperform” rating for the company in a research note on Friday, November 15th. Finally, Jefferies Financial Group upped their price target on Ascendis Pharma A/S from $174.00 to $196.00 and gave the company a “buy” rating in a research note on Tuesday, August 13th.

Institutional Investors Weigh In On Ascendis Pharma A/S

A number of hedge funds have recently added to or reduced their stakes in the business. Westfield Capital Management Co. LP increased its position in shares of Ascendis Pharma A/S by 3.4% during the third quarter. Westfield Capital Management Co. LP now owns 5,133,766 shares of the biotechnology company’s stock worth $766,523,000 after acquiring an additional 170,942 shares during the period. Avoro Capital Advisors LLC grew its stake in Ascendis Pharma A/S by 5.8% during the 2nd quarter. Avoro Capital Advisors LLC now owns 4,196,661 shares of the biotechnology company’s stock worth $572,341,000 after purchasing an additional 229,995 shares in the last quarter. Janus Henderson Group PLC increased its holdings in Ascendis Pharma A/S by 6.8% during the 3rd quarter. Janus Henderson Group PLC now owns 4,186,694 shares of the biotechnology company’s stock worth $625,075,000 after purchasing an additional 267,881 shares during the period. Capital International Investors raised its position in Ascendis Pharma A/S by 0.5% in the 1st quarter. Capital International Investors now owns 2,191,312 shares of the biotechnology company’s stock valued at $331,261,000 after purchasing an additional 10,044 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA boosted its stake in shares of Ascendis Pharma A/S by 9.1% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 1,866,986 shares of the biotechnology company’s stock valued at $278,760,000 after buying an additional 155,971 shares during the period.

Ascendis Pharma A/S Stock Performance

NASDAQ:ASND opened at $124.44 on Wednesday. Ascendis Pharma A/S has a one year low of $90.13 and a one year high of $161.00. The stock has a market cap of $7.55 billion, a PE ratio of -15.40 and a beta of 0.66. The stock has a 50 day moving average price of $132.59 and a 200 day moving average price of $132.38.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.54) by ($0.51). The business had revenue of $38.75 million during the quarter, compared to analyst estimates of $94.74 million. As a group, analysts predict that Ascendis Pharma A/S will post -7.3 earnings per share for the current fiscal year.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.